What Happened
A Reddit user posed this compelling question in the “Explain Like I’m Five” community, highlighting what scientists call “Peto’s Paradox.” Named after epidemiologist Richard Peto, this paradox describes the counterintuitive observation that cancer rates don’t correlate with body size across species. Blue whales, weighing up to 200 tons with an estimated 37 trillion cells, should theoretically have exponentially higher cancer rates than humans with our mere 37 trillion cells—yet they don’t.
The question touches on fundamental cancer biology: if cancer results from random cellular mutations during DNA replication, and larger animals have more cells dividing more frequently over longer lifespans, logic suggests they should be riddled with tumors. But nature has other plans.
Why It Matters
Understanding how large animals resist cancer could revolutionize human cancer treatment and prevention. Researchers are studying these natural anti-cancer mechanisms to develop new therapies, potentially unlocking treatments that could save millions of lives. The mechanisms these animals evolved over millions of years represent a vast library of biological solutions to one of humanity’s most persistent health challenges.
This research also illuminates how evolution shapes life at the cellular level, demonstrating that natural selection operates not just on visible traits but on microscopic biological processes that determine survival.
Background
Peto first described this paradox in the 1970s, noting that cancer rates vary surprisingly little across mammalian species despite dramatic differences in body size and lifespan. Mice, living two years with relatively few cells, develop cancer at rates similar to elephants, which live 60-70 years with vastly more cells.
Several evolutionary adaptations explain this phenomenon:
Enhanced DNA Repair: Large animals have evolved more sophisticated DNA repair mechanisms. Elephants possess 20 copies of the p53 gene—often called the “guardian of the genome”—compared to humans’ single copy. When cells detect DNA damage, p53 triggers repair processes or cell death to prevent cancerous transformation.
Hyper-Sensitive Tumor Suppression: Elephant cells undergo apoptosis (programmed cell death) at lower thresholds of DNA damage than human cells. While this might seem wasteful, it prevents potentially cancerous cells from surviving and multiplying.
Slower Metabolic Rates: Many large animals have proportionally slower metabolisms, reducing oxidative stress that can damage DNA. Whales’ extremely long lifespans (some bowhead whales live over 200 years) occur alongside remarkably stable cellular environments.
Improved Immune Surveillance: Larger animals have evolved more effective immune systems capable of detecting and destroying abnormal cells before they become tumors.
What’s Next
Scientists are translating these discoveries into potential human therapies. Researchers are developing drugs that mimic elephants’ enhanced p53 function, potentially giving human cells similar cancer resistance. Other studies focus on whale longevity genes that might extend healthy human lifespan.
The field of “evolutionary oncology” is expanding rapidly, with researchers studying everything from naked mole rats (which rarely develop cancer despite long lifespans) to Tasmanian devils (whose facial tumors threaten species survival) to understand cancer resistance mechanisms.
Clinical trials are beginning to test therapies based on these natural adaptations, though practical treatments remain years away. The research also raises intriguing questions about human evolution and whether our cancer susceptibility represents an evolutionary trade-off for other advantages like rapid growth and reproduction.